RB-190 Update

I'm grateful for the emails with encouragement and to request updates. Once again, I was fortunate that Michel and Mark at No Silver Bullet 4 PD also asked for an update.

Today, they posted my summary of activities to date and shared a vision for the coming months.

I did something for this half hour presentation that I did once before - spoke with no slides and working from an outline rather than a memorized speech. There were no teleprompters used. I just wanted to talk with you.

The last time I did this was for a keynote presentation at a stem cell conference. It seemed to go well. Then about 6 months later I was at a small group meeting when one of the participants introduced himself to the group by turning to me and raving about my speech without notes and without slides as novel and captivating. So hopefully this time goes over as well.

We are making progress. It is a slow process that requires incredible attention to detail and a ton of work on so many different aspects of product development. It's hard, and a large part of that is due to FDA regulations and oversight. And I love that burden because with it, we are forced to excel and focus on every step to make sure we are maximizing safety as we launch our clinical testing.

As we hit milestones, I'll share that here. And that will include disclosure of the locations for the clinical trial, the criteria for participation and the timelines.

You can also listen to my No Silver Bullet 4 PD presentation from June 2024 on Spotify or Apple Podcasts. Please share these widely. Send it to your doctors. Send it to your family. Send it to your friends. Send it to your old college buddies. I urge you to do so largely out of selfishness. We've raised over $1 million of the $6 million we need. And all that money has come from investors who read the weekly posts or found us on LinkedIn. So if you want to help, please send this around widely.

If you prefer to send something more technical, you can send this paper I published in the Journal of Neurology last year that reviews the science supporting our approach. And if a doctor is critical or unwilling to believe in the possibilities, remember that the experts selected by Michael J. Fox Foundation could not cite one piece of science to undermine our approach. Be confident. Be hopeful. Be confident. We're being productive.


Share This

About Jonathan Sackner-Bernstein, MD

Dr. Sackner-Bernstein shares his pursuit of conquering Parkinson's, using expertise developed as Columbia University faculty, FDA senior official, DARPA insider and witness to the toll of PD.
Dr. S-B’s Linkedin page

RightBrainBio, Inc. was incorporated in 2022 to develop tranformative therapies for people with Parkinson's.